No Data
No Data
IMMUNO-BIOLOGICAL LABORATORIES: Financial results briefing materials for the fiscal year ending 2024/3 (42nd term)
IMMUNO-BIOLOGICAL LABORATORIES: Summary of Financial Results for the Fiscal Year Ending March 31, 2024 [Japanese GAAP] (Consolidated)
Immuno Biological Labs Sees FY Net Y115.00M
Immuno-Biological Laboratories Co. Ltd. also released the following forecasts: GROUP Year Ending Mar 2025 Revenue Y925.00 mln Operating Profit Y120.
Classicom, Confidence I, etc.
<2351>ASJ upward revision, previous fiscal year operating profit forecast 102 million yen ← 80 billion yen <3286>Trust HD shareholder benefit plan newly established <3625> tech firm earnings forecast revision, current fiscal year sales forecast 5.00 billion yen ← 6.00 billion yen <3917>formulating a medium-term management plan involving iRidge from the fiscal year ending 25/3 to the fiscal year ending 27/3 <4165> Played revised upward, sales forecast for the current fiscal year ending 10.809 billion yen ← 10.666 billion yen <43
IMMUNO-BIOLOGICAL LABORATORIES: Notice regarding revisions to full-year earnings forecasts
Backstage [stocks that moved, stocks that were made]
*Hello's <2742> 4500 +21524/2 earnings forecast revised upward. *Motorbike King <3377> 533-44 The operating profit and loss for the first quarter was in deficit of 613 million yen. *Fujikoshi <6474> 3375-120 1st quarter operating profit decreased 69.8%. *Truss OP <6696> 337 +80 The report “Marubeni Information Systems sells power consumption reduction solutions” was viewed as material. *BIRDMAN <7063> 1198 +54 Kao “SPOT
No Data